Late relapses evolve from slow-responding subclones in t(12;21)-positive acute lymphoblastic leukemia: Evidence for the persistence of a preleukemic clone

Blood

Volumn 101, Issue 9, 2003, Pages 3635-3640

  Konrad, Marianne ^b   Metzler, Markus ^b   Panzer, Simon ^b   Östreicher, Iris ^b   Peham, Martina ^b   Repp, Reinald ^b   Haas, Oskar A ^b   Gadner, Helmut ^b   Panzer Grümayer, E Renate ^a  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CYTODIAGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER RISK; CASE REPORT; CHILD; CLONAL VARIATION; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE FUSION; GENE REARRANGEMENT; HUMAN; MALE; MOLECULAR GENETICS; PRELEUKEMIA; PRIORITY JOURNAL; RECURRENT CANCER; RELAPSE; STEM CELL; ACUTE LYMPHOCYTIC LEUKEMIA; CANCER STEM CELL; CELL CLONE; CELL SURVIVAL; CHROMOSOME 12; CHROMOSOME 21; FLUORESCENCE IN SITU HYBRIDIZATION; GENE TRANSLOCATION; GENETICS; INFANT; PATHOLOGY; PRESCHOOL CHILD; RECURRENT DISEASE; REMISSION; RETROSPECTIVE STUDY; TIME; ULTRASTRUCTURE;

ANTINEOPLASTIC AGENT; ONCOPROTEIN; TEL AML1 FUSION PROTEIN; TEL-AML1 FUSION PROTEIN; TRANSCRIPTION FACTOR RUNX1; TUMOR MARKER; TUMOR PROTEIN;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SURVIVAL; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 12; CHROMOSOMES, HUMAN, PAIR 21; CLONE CELLS; CORE BINDING FACTOR ALPHA 2 SUBUNIT; FEMALE; GENE REARRANGEMENT, B-LYMPHOCYTE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PRELEUKEMIA; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELLS;

EID: 0037866469     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-10-3252     Document Type: Article

References (45)

1. Loh ML, Rubnitz JE. TEL/AML1-positive pediatric leukemia: prognostic significance and therapeutic approaches. Curr Opin Hematol. 2002;9:345-352.
2. Shurtleff SA, Buijs A, Behm FG, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia. 1995;9:1985-1989.
3. Rubnitz JE, Shuster JJ, Land VJ, et al. Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group study. Blood. 1997;89:1143-1146.
4. Maloney K, McGavran L, Murphy J, et al. TEL-AML1 fusion identifies a subset of children with standard risk acute lymphoblastic leukemia who have an excellent prognosis when treated with therapy that includes a single delayed intensification. Leukemia. 1999;13:1708-1712.
5. McLean TW, Ringold S, Neuberg D, et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood. 1996;88:4252-4258.
6. Loh ML, Silverman LB, Young ML, et al. Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood. 1998;92:4792-4797.
7. Harbott J, Viehmann S, Borkhardt A, Henze G, Lampert F. Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood. 1997;90:4933-4937.
8. Seeger K, Adams HP, Buchwald D, et al. TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin-Frankfurt-Munster Study Group. Blood. 1998;91:1716-1722.
9. Rubnitz JE, Behm FG, Wichlan D, et al. Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup. Leukemia. 1999;13:19-21.
10. Seeger K, Buchwald D, Taube T, et al. TEL-AML1 positivity in relapsed B cell precursor acute lymphoblastic leukemia in childhood. Berlin-Frankfurt-Munster Study Group. Leukemia. 1999;13:1469-1470.
11. Wiemels JL, Cazzaniga G, Daniotti M, et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet. 1999;354:1499-1503.
12. Wiemels JL, Ford AM, van Wering ER, Postma A, Greaves M. Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML1 gene fusion in utero. Blood. 1999;94:1057-1062.
13. Ford AM, Bennett CA, Price CM, Bruin MC, van Wering ER, Greaves M. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc Natl Acad Sci U S A. 1998;95:4584-4588.
14. Romana SP, Le Coniat M, Poirel H, Marynen P, Bernard O, Berger R. Deletion of the short arm of chromosome 12 is a secondary event in acute lymphoblastic leukemia with t(12;21). Leukemia. 1996;10:167-170.
15. Raynaud S, Cave H, Baens M, et al. The 12;21 translocation involving TEL and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia. Blood. 1996;87:2891-2899.
16. Steward CG, Goulden NJ, Katz F, et al. A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor delta gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia. Blood. 1994;83:1355-1362.
17. Szczepanski T, Willemse MJ, Brinkhof B, van Wering ER, van der BM, van Dongen JJ. Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood. 2002;99:2315-2323.
18. Levasseur M, Maung ZT, Jackson GH, Kemahan J, Proctor SJ, Middleton PG. Relapse of acute lymphoblastic leukaemia 14 years after presentation: use of molecular techniques to confirm true reemergence. Br J Haematol. 1994;87:437-438.
19. Vora A, Frost L, Goodeve A, et al. Late relapsing childhood lymphoblastic leukemia. Blood. 1998;92:2334-2337.
20. Beishuizen A, Hahlen K, Hagemeijer A, et al. Multiple rearranged immunoglobulin genes in childhood acute lymphoblastic leukemia of precursor B-cell origin. Leukemia. 1991;5:657-667.
21. Deane M, Pappas H, Norton JD. Immunoglobulin heavy chain gene fingerprinting reveals widespread oligoclonality in B-lineage acute lymphoblastic leukaemia. Leukemia. 1991;5:832-838.
22. Steenbergen EJ, Verhagen OJ, van Leeuwen EF, dem Borne AE, van der Schoot CE. Distinct ongoing Ig heavy chain rearrangement processes in childhood B-precursor acute lymphoblastic leukemia. Blood. 1993;82:581-589.
23. Ford AM, Fasching K, Panzer-Grümayer ER, Koenig M, Haas OA, Greaves MF. Origins of "late" relapse in childhood acute lymphoblastic leukemia with TEL-AML1 fusion genes. Blood. 2001;98:558-564.
24. Szczepanski T, van der Velden V, van Dongen JJ. Real-time quantitative (RQ)-PCR for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Hematologica. In press.
25. Szczepanski T, Pongers-Willemse MJ, Langerak AW, et al. Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage. Blood. 1999;93:4079-4085.
26. Pongers-Willemse MJ, Seriu T, Stolz F, et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:110-118.
27. Ghali DW, Panzer S, Fischer S, et al. Heterogeneity of the T-cell receptor delta gene indicating subclone formation in acute precursor B-cell leukemias. Blood. 1995;85:2795-2801.
28. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95:3310-3322.
29. Henze G. Chemotherapy for relapsed childhood acute lymphoblastic leukemia. Int J Pediatr Hematol Oncol. In press.
30. Wasserman R, Galili N, Ito Y, Reichard BA, Shane S, Rovera G. Predominance of fetal type DJH joining in young children with B precursor lymphoblastic leukemia as evidence for an in utero transforming event. J Exp Med. 1992;176:1577-1581.
31. Steenbergen EJ, Verhagen OJ, van Leeuwen EF, et al. B precursor acute lymphoblastic leukemia third complementarity-determining regions predominantly represent an unbiased recombination repertoire: leukemic transformation frequently occurs in fetal life. Eur J Immunol. 1994;24:900-908.
32. Schneider M, Panzer S, Stolz F, Fischer S, Gadner H, Panzer-Grümayer ER. Crosslineage TCR delta rearrangements occur shortly after the DJ joinings of the IgH genes in childhood precursor B ALL and display age-specific characteristics. Br J Haematol. 1997;99:115-121.
33. Panzer-Grümayer ER, Fasching K, Panzer S, et al. Nondisjunction of chromosomes leading to hyperdiploid childhood B-cell precursor acute lymphoblastic leukemia is an early event during leukemogenesis. Blood. 2002;100:347-349.
34. Fasching K, Panzer S, Haas OA, et al. Presence of N regions in the clonotypic DJ rearrangements of the immunoglobulin heavy-chain genes indicates an exquisitely short latency in t(4;11)-positive infant acute lymphoblastic leukemia. Blood. 2001;98:2272-2274.
35. Greaves M. Molecular genetics, natural history and the demise of childhood leukaemia. Eur J Cancer. 1999;35:173-185.
36. Mori H, Colman SM, Xiao Z, et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci U S A. 2002;99:8242-8247.
37. Kubagawa H, Cooper MD, Carroll AJ, Burrows PD. Light chain gene expression before heavy chain gene, rearrangement in pre-B cells transformed by Epstein-Barr virus. Proc Natl Acad Sci U S A. 1989;86:2356-2360.
38. Fasching K, Panzer S, Haas OA, Marschalek R, Gadner H, Panzer-Grümayer ER. Presence of clone-specific antigen receptor gene rearrangements at birth indicates an in utero origin of diverse types of early childhood acute lymphoblastic leukemia. Blood. 2000;95:2722-2724.
39. Wiemels JL, Xiao Z, Buffler PA, et al. In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood. 2002;99:3801-3805.
40. Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood. 1993;82:712-715.
41. Miyamoto T, Nagafuji K, Akashi K, et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood. 1996;87:4789-4796.
42. Miyamoto T, Weissman IL, Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci U S A. 2000;97:7521-7526.
43. de Haas V, Verhagen OJ, dem Borne AE, Kroes W, van den BH, van der Schoot CE. Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapy. Leukemia. 2001;15:134-140.
44. Rompaey LV, Potter M, Adams C, Grosveld G. Tel induces a G1 arrest and suppresses Ras-induced transformation. Oncogene. 2000;19:5244-5250.
45. Eguchi-Ishimae M, Eguchi M, Ishii E, et al. Breakage and fusion of the TEL (ETV6) gene in immature B lymphocytes induced by apoptogenic signals. Blood. 2001;97:737-743.